Nothing said here yet.
to join the conversation.
| Kevin Hern | Sell | $8.0K | Thu, Sep 10 | Tue, Sep 15 |
| Kevin Hern | Sell | $8.0K | Mon, Aug 31 | Tue, Sep 15 |
| Scott Scott Franklin | Buy | $8.0K | Wed, Aug 26 | Wed, Sep 2 |
| Alan Armstrong | Buy | $32.5K | Mon, Mar 30 | Tue, Jul 21 |
Novo Nordisk has seen its share price fall sharply in recent years, which puts fresh focus on whether the current US$40.00 level is still aligned with what its earnings can justify.
Eli Lilly trial data showing retatrutide outperforming Ozempic has sharpened the competitive focus on Novo Nordisk (NYSE:NVO), just as the Danish drugmaker outlines longer term 2030 goals.
Novo Nordisk (NYSE:NVO) set new 2030 business targets as it responds to rising competition in GLP-1 diabetes and obesity drugs.
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The company’s comeback strategy looks sound.
Novo Nordisk (NYSE:NVO) faces tougher GLP-1 competition after Lilly’s retatrutide outperformed Ozempic in a diabetes trial, Citi said, maintaining its ‘neutral/high risk’ rating and a Dkr296.00 target price.
Eli Lilly (NYSE:LLY) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely moving.
New data on Novo's investigational obesity treatment, CagriSema, explores changes in weight-related quality of life and the potential for weight loss at lower doses1,2 Wegovy® data includes new insights into real-world patient treatment experience in adults…
Novo Nordisk has seen its share price come under pressure, and the question for you now is whether the current valuation is still supported by the earnings power of the business.
Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study, the company said Wednesday.
More treatment options. Transparent pricing. A new way for employers to put obesity care within reach. NEW YORK, Oct.
The PLATINUM-Truveta retrospective cohort analysis compared the effectiveness of semaglutide 2.4 mg and resmetirom on liver enzymes and cardiometabolic markers in people with MASH New post hoc data from ESSENCE examines changes in liver related parameters…